Clinical studies examining sermorelin therapy have not demonstrated any causal link between this peptide treatment and cancer development in humans
Maintaining balanced IGF-1 + IGFBP-3 levels supports healthy tissue repair without tipping into excessive growth
Growth hormone production decreases dramatically in most adults after age 30 and may result in the physical breakdown of the human body resulting in injury, fatigue, lack of energy, and aging in general
The non-DAC form (Mod GRF 1-29) is short-acting, producing a brief GH pulse, and is dosed more frequently
Protocol selection should reflect individual goals, metabolic status, and clinical oversight
Evidence remains mixed and often limited to small trials or animal models